Injectable Poly-L-Lactic Acid for Volumization and Adipogenesis of the Hip Dell

Inclusion Criteria: * Adult females aged 30 to 60 years * Subjects in good general health based on investigator's judgment and medical history * Moderate to severe hip dell volume deficit as determined by the investigators * Must be willing to give and sign an informed consent form and photographic release form * Must have a stable body weight for at least six (6) months prior to study entry * Must be willing to maintain usual sun exposure, diet, and exercise routines for the duration of the study * Subject agrees to avoid tanning or use of sunless tanner during the entire course of the study * Negative urine pregnancy test result at the time of study entry (if applicable) * For female subjects of childbearing potential, must be willing to use an acceptable form of birth control during the entire course of the study. All systemic birth control measures must be in consistent use for at least 30 days prior to study enrollment. * A female is considered of childbearing potential unless she is postmenopausal, without a uterus and/or both ovaries, or has had a bilateral tubal ligation. * Acceptable methods of birth control are: oral contraceptives, contraceptive patches/rings/implants, Implanon®, Depo-Provera®, double-barrier methods (e.g., condoms and spermicide), abstinence, and/or vasectomy of partner with a documented second acceptable method of birth control, should the subject become sexually active. * Must be willing to comply with study treatments and complete the entire course of the study Exclusion Criteria: * Liposuction to bilateral hips, flanks, thighs, buttocks during the 12-month period prior to study treatment or any time during the course of the study * Mesotherapy, dermal fillers, biostimulatory injectables, fat grafting, radiofrequency device treatments, microfocused ultrasound device treatments, laser and light-based device treatments, microneedling, cryolipolysis, high intensity focused electromagnetic energy device treatment, or surgery (i.e., lower body lift, buttocks augmentation, abdominoplasty, etc.) during the 12-month period before study treatment c) Any investigational treatment for a volume deficit of the bilateral hip dell areas during the 12-month period before the study treatment d) Massage therapy during the 3-month period before study treatment. e) Creams/cosmeceuticals and/or home therapies to promote plumping of the bilateral hip dell area during the four-week period before study treatment f) Subjects with scarring in the treatment areas g) History of thrombosis, post-thrombosis syndrome, or any vascular disorder of the bilateral lower extremities * Any history of bleeding or coagulation disorders i) Subjects with tattoos or permanent implants in the treatment areas j) Subjects with a significant history or current evidence of a medical, psychological, or other disorder that, in the investigator's opinion, would preclude enrollment into the study * Subjects with a history of or presence of any skin condition/disease (including but not limited to any visible rash, atopic dermatitis, psoriasis, actinic keratoses, keratinocyte carcinoma, melanoma, etc.) in the treatment area that might interfere with the diagnosis or evaluation of study parameters * History of keloid or hypertrophic scarring * Subjects with an active bacterial, viral, or fungal infection of the treatment areas * Subjects who spray tanned or used sunless tanners in the treatment areas four (4) weeks prior to study treatment * History of lidocaine sensitivity deemed by the investigator to preclude the subject from enrolling into the study * Subjects planning any cosmetic procedure to the treatment areas during the study period, other than the treatment that will be performed by the investigator * Presence of incompletely healed wound(s) in the treatment area * Subjects who are on an immunosuppressant or have an autoimmune condition * Female subjects who are pregnant, planning a pregnancy, or breast feeding during the study * Current participation or participation within 30 days prior to the start of this study in a drug or other investigational research study